Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

For much of the past century, Alzheimer's disease has been one of medicine's most daunting frontiers—biologically complex, ...

Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...

Biomarker development is hardly coextensive with drug development, but in every developmental stage—from exploratory research to clinical trial to therapeutic application—there is significant overlap.

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

As molecular biomarkers go, proteins are possibly the most universally affected by disease state. Protein signatures encompass not only total levels of expression, but predominance of different ...

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Alzheimer’s Disease research is advancing with developments like Roche’s new biomarker blood test. Yet 98% of AD clinical ...

Researchers from Critical Path Institute's ® (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, ...